PCG Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$277K Hold
4,800
– – 0.2% 75
2026
Q1
$291K Hold
4,800
– – 0.23% 69
2025
Q4
$264K Sell
4,800
-225
-4% -$10.8K 0.21% 69
2025
Q3
$227K Sell
5,025
-125
-2% -$5.84K 0.18% 74
2025
Q2
$238K Hold
5,150
– – 0.2% 71
2025
Q1
$314K Sell
5,150
-100
-2% -$5.83K 0.29% 59
2024
Q4
$297K Buy
+5,250
New +$293K 0.26% 65

Other funds holding BMY

PCG Asset Management's BMY Position: Q2 2026 in Review

PCG Asset Management held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 4,800 shares worth $277K. The position accounts for 0.2% of the portfolio, ranked #75.

PCG Asset Management first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $314K in Q1 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • PCG Asset Management held 4,800 shares of Bristol-Myers Squibb worth $277K as of Q2 2026.
  • PCG Asset Management left its Bristol-Myers Squibb share count unchanged in Q2 2026.
  • Bristol-Myers Squibb made up 0.2% of PCG Asset Management's portfolio in Q2 2026, its #75 holding.
  • PCG Asset Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
  • PCG Asset Management's Bristol-Myers Squibb position peaked at $314K in Q1 2025.
  • 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on PCG Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.